Clinical Trial Update: A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia [Phase 3]

View source ↗

Summary

A Phase 3 trial of tolvaptan for euvolemic and hypervolemic hyponatremia in children and adolescents has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Hyponatremia | Phase 3 | Status: WITHDRAWN